Over 3 million surgeries are performed each year in the abdomen and pelvis, and accidental injury to the ureter during these cases is a $3.2 billion problem. Current techniques and methods to prevent ureter injury are lacking as they are either expensive and do not actually prevent injury, or are time consuming and inherently risk injury to the ureters. Allotrope Medical improves patient outcomes through reliable ureter identification which shortens OR time, decreases complications, and has the potential to decrease hospital length of stay at a reduced overall cost.
Allotrope has created a hand held, single use, battery powered device that quickly, easily and safely allows the surgeon to identify the ureter during minimally invasive surgery using electrical stimulation. Target users for the technology will be Ob/Gyn, general and colorectal surgeons and other specialties such as Urology and Vascular surgery also seeing applications in their field. The Allotrope technology shortens OR time, bypasses the need for additional expensive procedures, and can decrease accidental injuries to patients, all with a cost effective device.
Allotrope Medical’s device is currently pre-FDA and is hand held, stand-alone, with demonstrated efficacy in large animal models. The company’s next milestones are engagement with a product design/development firm, finalizing the alpha prototype, FDA clearance through the 510(k) pathway, and entering the marketplace Q1 of 2019. To date, Allotrope has received $350k in seed funding and is seeking $3M for Series A which will allow the company to complete planned milestones and gain early entry into hospitals.